On average, prognosticators following the company were modeling for $6.18 billion on the top line, and an adjusted net profit of $3.84 per share.Yet the gains and additions posted by some of Amgen's smaller and newer treatments -- notably the psoriasis drug Otezla, purchased last year from Celgene -- more than compensated for the declines elsewhere in the portfolio.